TCR-engineered T Cells in Solid Tumors: IMA202-101
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 16
Summary
- Conditions
- Cancer
- Hepatocellular Cancer
- Hepatocellular Carcinoma
- Liver Cancer
- Lung Cancer
- Nonsmall Cell Lung Cancer
- Solid Tumor, Adult
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and the Main biomarkers screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA202 product. MANUFACTURING: IMA202 product will be made from ...
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and the Main biomarkers screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA202 product. MANUFACTURING: IMA202 product will be made from the patient's white blood cells. TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA202 product infusion to improve the duration of time that IMA202 product stays in the body. The patient will be admitted to the hospital during the treatment. After the IMA202 product infusion, a low dose of IL-2 will be given twice daily for a period of time. Patients will be closely monitored for safety and for a total of 3 years post IMA202 infusion.
Tracking Information
- NCT #
- NCT03441100
- Collaborators
- Not Provided
- Investigators
- Study Director: Cedrik Britten, M.D. Immatics US, Inc. Principal Investigator: Apostolia Tsimberidou, M.D., Ph.D. M.D. Anderson Cancer Center
Get Well Soon